. Author manuscript; available in PMC: 2012 Jan 1.

Published in final edited form as: Am J Obstet Gynecol. 2010 Nov 3;204(1):56.e1–56.e6. doi: 10.1016/j.ajog.2010.08.023

Table 3.

Oxytocin treatment measurements

Characteristic	PPH atony (n=54)	Control (n=54)	p-value
Total oxytocin dose, AUC, mU ^a	10054 ± 11340	3762 ± 7093	<0.001
Time oxytocin start to delivery, min ^a	684 ± 593	330 ± 526	<0.001
Total time of oxytocin infusion, min ^a	628 ± 574	294 ± 467	<0.001
Oxytocin max dose, mU/min ^a	16.6 ± 14.7	7.0 ± 10.9	<0.001
Time oxytocin max dose to delivery, min ^b	109 ± 38	87 ± 38	0.64
Time oxytocin discontinuation to delivery, min ^b	37 ± 11	31 ± 11	0.58
Oxytocin dose at delivery, mU/min ^a	5.6 ± 9.9	2.5 ± 6.6	0.045
Subjects with oxytocin infusion on at delivery, n (%) ^c,^d	19 (50)	9 (45)	0.72
Subjects with maximal oxytocin infusion on at delivery, n (%) ^c,^d	10 (26.3)	7 (35)	0.49

AUC, area under the curve

Values are mean ± SD, p-value for paired t-test

Values are mean ± SE (paired test). These characteristics calculated only for those paired subjects receiving oxytocin.

These characteristics calculated for all subjects receiving oxytocin, PPH atony group n=38, control n=20

Comparison made with chi-square